Chugai Pharmaceutical Company Profile - aVenture Research
Chugai Pharmaceutical operates as a prescription drug company built around oncology and specialty medicine rather than a single therapy class, spanning research, development, manufacturing, and marketing across oncology, specialty, and out-licensed medicine categories. In Japan, it also markets drugs for bone and joint, autoimmune, renal, neurological, and hemophilia areas besides oncology.
Chugai develops macrocyclic peptide drugs as a third modality after antibody and small molecule drugs, extending its antibody and small molecule discovery approach. These macrocyclic peptides aim to merge the benefits of small molecules with those of antibody drugs.
Hemlibra, also known as emicizumab, is Chugai's prescribed humanized bispecific monoclonal antibody that acts as an anti-coagulation factor IXa/X agent.